Capital Insight Partners LLC Sells 1,307 Shares of Chemed Corporation $CHE

Key Points

• Capital Insight Partners LLC decreased its holdings in Chemed Corporation by 12.4%, selling 1,307 shares in the second quarter and now owning 9,247 shares valued at approximately $4.5 million.
• Chemed Corporation missed earnings expectations for the last quarter, reporting $4.27 EPS against a consensus estimate of $6.02, with revenue of $618.8 million, below the anticipated $650.6 million.
• The company announced a recent dividend increase from $0.50 to $0.60 per share, reflecting a positive change and an annualized yield of 0.5%.

Capital Insight Partners LLC reduced its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 12.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,247 shares of the company's stock after selling 1,307 shares during the period. Capital Insight Partners LLC owned 0.06% of Chemed worth $4,503,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Alpine Bank Wealth Management purchased a new position in shares of Chemed during the first quarter valued at approximately $29,000. HM Payson & Co. bought a new position in Chemed during the 1st quarter valued at approximately $30,000. SVB Wealth LLC bought a new position in Chemed during the 1st quarter valued at approximately $30,000. Whipplewood Advisors LLC raised its stake in Chemed by 54.5% during the first quarter. Whipplewood Advisors LLC now owns 51 shares of the company's stock valued at $31,000 after buying an additional 18 shares during the last quarter. Finally, WPG Advisers LLC bought a new stake in Chemed in the first quarter worth $32,000. Hedge funds and other institutional investors own 95.85% of the company's stock.

Chemed Stock Up 2.6%

Shares of NYSE CHE opened at $462.30 on Monday. The firm's 50-day moving average price is $450.29 and its 200-day moving average price is $520.75. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60. The company has a market cap of $6.74 billion, a PE ratio of 23.77, a PEG ratio of 2.69 and a beta of 0.46.

Chemed (NYSE:CHE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by ($1.75). The company had revenue of $618.80 million during the quarter, compared to analysts' expectations of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%.The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.47 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities research analysts anticipate that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Monday, August 11th were issued a $0.60 dividend. This is a positive change from Chemed's previous quarterly dividend of $0.50. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Monday, August 11th. Chemed's dividend payout ratio is currently 12.34%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada reduced their price target on Chemed from $640.00 to $589.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Oppenheimer reduced their price objective on shares of Chemed from $650.00 to $580.00 and set an "outperform" rating for the company in a research note on Thursday, July 31st. Jefferies Financial Group upgraded shares of Chemed from a "hold" rating to a "buy" rating and upped their target price for the stock from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Bank of America cut their price target on shares of Chemed from $610.00 to $595.00 and set a "buy" rating on the stock in a report on Wednesday, September 10th. Finally, Wall Street Zen downgraded shares of Chemed from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $578.50.

Insider Buying and Selling at Chemed

In related news, Director Patrick P. Grace sold 150 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the transaction, the director owned 3,397 shares of the company's stock, valued at approximately $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Nicholas Michael Westfall sold 10,012 shares of the business's stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $421.91, for a total transaction of $4,224,162.92. The disclosure for this sale can be found here. 3.29% of the stock is owned by corporate insiders.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.